Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Sonus Pharmaceuticals

This article was originally published in The Gray Sheet

Executive Summary

Sonus Pharmaceuticals: Receives $3 mil. milestone payment from Daiichi Pharmaceutical of Japan for successful completion of Phase II U.S. clinical trials of Sonus' EchoGen ultrasound contrast agent for detection of myocardial perfusion. Daiichi has an exclusive marketing license for the fluorocarbon-based agent in Japan and nine other Pacific Rim countries. The trials, completed in June, involved 60 patients at two clinical sites. Sonus expects to begin Phase III trials for EchoGen, involving between 150-250 patients at up to 21 sites, by the end of the year...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel